Pregled bibliografske jedinice broj: 523303
The Antihypertensive Effect of the GLP-1 Mimetic Exenatide
The Antihypertensive Effect of the GLP-1 Mimetic Exenatide // Abstracts of the 5th Central European Meeting on Hypertension ; u: Kidney & blood pressure research 32 / Tesar, Vladimir (ur.).
Basel: Karger Publishers, 2009. str. 326-326 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 523303 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The Antihypertensive Effect of the GLP-1 Mimetic Exenatide
Autori
Baretić, Maja ; Pavlić-Renar, Ivana ; Aganović, Izet ; Koršić, Mirko ; Kaštelan, Darko ; Giljević, Zlatko ; Jelčić, Jozo ; Dušek, Tina.
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts of the 5th Central European Meeting on Hypertension ; u: Kidney & blood pressure research 32
/ Tesar, Vladimir - Basel : Karger Publishers, 2009, 326-326
Skup
Central European Meeting on Hypertension
Mjesto i datum
Zagreb, Hrvatska, 22.10.2009. - 25.10.2009
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
hypertension; GLP-1; diabetes mellitus
Sažetak
Glucagon-like peptide-1 (GLP 1) is an incretin, a gastrointestinal hormone secreted from the gut after a meal. The positive glucoregulatory properties of GLP 1 are well known: it inhibits glucagon release, delays gastric emptying and augments satiety with the consequence of weight loss. The incretin mimetic exenatide, a pharmacological agent with a structure similar to that of GLP 1, has all the above properties of endogenous GLP 1. We examined 40 patients with type 2 diabetes mellitus unable to achieve adequate glycemic control with sulphonylurea and/or metformin. Patients were without antihypertensive therapy, or on stable one. Exenatide was added to therapy for 52 weeks: 5 mg of exenatide BID for the first 4 weeks, and then till the end of the study 10 mg BID. At the end of the trial, statistically significant mean reduction in both systolic blood pressure −4.65 mmHg ; p = 0.008582) and diastolic blood pressure (−1.48 mmHg ; p = 0.006286) was observed. GLP 1 receptors are found all over the body, as well as in the kidneys. Both GLP 1 and exenatide enhance sodium excretion, and their diuretic properties could explain the lowering of blood pressure. Do we have a drug that influences three elements of the metabolic syndrome: diabetes, obesity, and hypertension?
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinički bolnički centar Zagreb
Profili:
Maja Baretić
(autor)
Ivana Pavlić-Renar
(autor)
Izet Aganović
(autor)
Darko Kaštelan
(autor)
Jozo Jelčić
(autor)
Tina Dušek
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus
- MEDLINE